The University of Cambridge has revealed that a new vaccine antigen technology could help enhance vaccine candidates to tackle potential future viruses and variants.

Developed by the University of Cambridge and its spin-out company, Digitally Immune Optimised Synthetic Vaccines (DIOSynVax), the technology could enhance vaccine protection against global threats, including existing and future virus outbreaks.

omit

[PMLiIVE, 2023.10.5, https://www.pmlive.com/pharma_news/new_vaccine_technology_could_help_fight_future_viruses_and_variants_1501562]